| Size | Price | Stock | Qty |
|---|---|---|---|
| 500mg |
|
||
| Other Sizes |
| Targets |
Endogenous Metabolite
|
|---|---|
| ln Vitro |
Research indicates that Phosphocreatine possesses neuroprotective and renoprotective potential. In terms of neuroprotection, Phosphocreatine (5-20 mM, 24 h) attenuates MGO (Methylglyoxal)-induced PC12 cell damage, inhibits apoptosis [3], and prevents the loss of mitochondrial membrane permeability [3]. Its mechanism of action involves normalizing mitochondrial function and reducing oxidative stress through the Akt-mediated Nrf2/HO-1 pathway [3]. Regarding renoprotection, Phosphocreatine (5-40 mM, 24 h) protects NRK-52E cells from MGO-induced kidney injury in a concentration-dependent manner [4], and its application at 10-40 mM for 4 h inhibits the production of renal oxidative stress metabolites [4].
|
| ln Vivo |
In the context of DOX-induced cardiotoxicity, Phosphocreatine treatment (200 mg/kg, i.p., every other day for 7 weeks) attenuated oxidative stress and apoptosis, and rescued myocardial tissue from necroptosis [2]. Additionally, in a diabetic nephropathy model, Phosphocreatine (20-40 mg/kg, i.v., daily for 6 weeks) demonstrated renoprotective effects by preserving renal function in Sprague-Dawley rats [4].
|
| References | |
| Additional Infomation |
Phosphocreatine has been reported in Homo sapiens, cattle, and other organisms with relevant data. See also: Phosphocreatine (preferred).
|
| Molecular Formula |
C4H11N3NAO6P
|
|---|---|
| Molecular Weight |
251.1102
|
| Exact Mass |
254.999
|
| CAS # |
922-32-7
|
| Related CAS # |
Phosphocreatine;67-07-2;Sodium creatine phosphate dibasic tetrahydrate;71519-72-7;Phosphocreatine dipotassium;18838-38-5;Phosphocreatine disodium hydrate;19333-65-4;18838-38-5;67-07-2;19333-65-4;71519-72-7;922-32-7;
|
| PubChem CID |
587
|
| Appearance |
White to off-white solid powder
|
| LogP |
-2.6
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
13
|
| Complexity |
271
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CN(CC(=O)O)C(=NP(=O)([O-])[O-])N.[Na+].[Na+]
|
| InChi Key |
DRBBFCLWYRJSJZ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C4H10N3O5P/c1-7(2-3(8)9)4(5)6-13(10,11)12/h2H2,1H3,(H,8,9)(H4,5,6,10,11,12)
|
| Chemical Name |
2-[methyl-(N'-phosphonocarbamimidoyl)amino]acetic acid
|
| Synonyms |
phosphocreatine disodium salt; 922-32-7; Creatine phosphate disodium salt; disodium;2-[methyl-(N'-phosphonatocarbamimidoyl)amino]acetic acid; Disodium Phosphocreatine Hydrate;
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~125 mg/mL (~490.04 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 100 mg/mL (392.03 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
(Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.9823 mL | 19.9116 mL | 39.8232 mL | |
| 5 mM | 0.7965 mL | 3.9823 mL | 7.9646 mL | |
| 10 mM | 0.3982 mL | 1.9912 mL | 3.9823 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
